338 related articles for article (PubMed ID: 27142424)
1. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
3. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract][Full Text] [Related]
6. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
[TBL] [Abstract][Full Text] [Related]
7. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
8. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
10. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
[TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
12. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial.
von Arx C; Della Vittoria Scarpati G; Cannella L; Clemente O; Marretta AL; Bracigliano A; Picozzi F; Iervolino D; Granata V; Modica R; Bianco A; Mocerino C; Di Mauro A; Pizzolorusso A; Di Sarno A; Ottaiano A; Tafuto S;
ESMO Open; 2024 May; 9(5):103003. PubMed ID: 38615472
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
14. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
15. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma.
Azoulay A; Cros J; Vullierme MP; de Mestier L; Couvelard A; Hentic O; Ruszniewski P; Sauvanet A; Vilgrain V; Ronot M
Diagn Interv Imaging; 2020 Dec; 101(12):821-830. PubMed ID: 32709455
[TBL] [Abstract][Full Text] [Related]
16. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
17. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
[TBL] [Abstract][Full Text] [Related]
18. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
20. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
